Time to evolve: predicting engineered T cell-associated toxicity with next-generation models.

Area of Science:

• Oncology
• Immunotherapy
• Preclinical Research

Background:

• Engineered T-cell therapies, like CAR and TCR T cells, offer clinical benefits for certain cancers but are linked to severe adverse events such as cytokine release syndrome and neurotoxicity.
• These toxicities limit the widespread application of these advanced cancer treatments.
• Current preclinical models have historically failed to accurately predict severe toxicities observed in human clinical trials.

Purpose of the Study:

• To review existing preclinical models for assessing engineered T-cell therapy safety.
• To highlight the limitations of current models in predicting clinical toxicities.
• To propose improvements for developing more predictive preclinical models.

Main Methods:

• Review of existing literature on preclinical models for engineered T-cell therapy safety assessment.
• Analysis of limitations in current models regarding prediction of cytokine release syndrome and neurotoxicity.
• Discussion of ongoing efforts, including humanized mouse models, to improve predictive value.

Main Results:

• Existing preclinical models have shown inadequacy in predicting severe adverse events associated with engineered T-cell therapies.
• Recent advancements include the development of humanized mouse models aiming for better recapitulation of patient toxicities.
• The T2EVOLVE consortium is focused on creating higher-predictive preclinical models and tools.

Conclusions:

• There is a critical need for improved preclinical models to accurately assess the safety of engineered T-cell therapies.
• Enhanced models are essential for accelerating the clinical translation of promising T-cell products.
• Future research should focus on developing and validating novel models that better predict clinical safety and efficacy.